The treatment candidate, ZRC-3308, was earlier shown to reduce lung damage during animal trials, the drugmaker said, adding it was found to be safe and well-tolerated. The therapy is a cocktail of two monoclonal antibodies, which mimic natural antibodies that the body generates to fight infection., The treatment candidate, ZRC-3308, was earlier shown to reduce lung damage during animal trials, the drugmaker said, adding it was found to be safe and well-tolerated. The therapy is a cocktail of two monoclonal antibodies, which mimic natural antibodies that the body generates to fight infection., , Read More
AAS Yoga
Go for Euphoria – Illness to Wellness the Natural Way